ProQR (PRQR)
NASDAQ:PRQR
Top Page
ProQR
(NASDAQ:PRQR)
Select Model
Select Model
Rating:46Neutral
Price Target:
$1.50
▲(0.00% Upside)
Action:ReiteratedDate:03/14/26
The score is primarily constrained by weak financial performance—ongoing losses, a return to heavier cash burn, and a declining equity base that increases funding risk. Technicals are moderately supportive in the near term (above short-term moving averages with neutral momentum) but remain challenged longer term (below 100/200-day averages). Valuation is also pressured due to negative earnings and no indicated dividend yield.
Positive Factors
Platform & Pipeline Expansion
ProQR’s Axiomer platform has produced multiple development candidates, diversifying clinical risk across indications. A broader pipeline increases the chance of a clinical success, supports partnering options, and turns the company into a platform play rather than a single-asset biotech, strengthening long-term commercial optionality.
Negative Factors
Persistent Cash Burn
The company reverted to heavier cash outflows in 2024–2025 after a one-year improvement, indicating unstable cash generation. Sustained negative operating and free cash flow increases the probability of future financing or dilution and forces prioritization of programs over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Platform & Pipeline Expansion
ProQR’s Axiomer platform has produced multiple development candidates, diversifying clinical risk across indications. A broader pipeline increases the chance of a clinical success, supports partnering options, and turns the company into a platform play rather than a single-asset biotech, strengthening long-term commercial optionality.
Read all positive factors
ProQR (PRQR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$158.04M
Dividend YieldN/A
Average Volume (3M)534.76K
Price to Earnings (P/E)―
Beta (1Y)1.91
Revenue Growth-11.99%
EPS Growth-42.04%
CountryUS
Employees166
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.09
Shares Outstanding105,361,060
10 Day Avg. Volume796,312
30 Day Avg. Volume534,757
Financial Highlights & Ratios
PEG Ratio-0.38
Price to Book (P/B)3.67
Price to Sales (P/S)11.85
P/FCF Ratio-3.50
Enterprise Value/Market Cap0.37
Enterprise Value/Revenue3.69
Enterprise Value/Gross Profit3.85
Enterprise Value/Ebitda-1.45
Forecast
1Y Price Target
$8.25Price Target Upside450.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.51
Revenue Forecast (FY)$22.76M
ProQR Business Overview & Revenue Model
Company Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate tri...
How the Company Makes Money
null...
ProQR Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
52
Neutral
Cash Flow
31
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 15.28M | 18.91M | 6.51M | 3.59M | 1.33M |
| Gross Profit | 12.68M | 18.91M | 6.51M | 3.59M | 1.33M |
| EBITDA | -39.56M | -24.12M | -24.10M | -56.46M | -54.95M |
| Net Income | -40.52M | -27.76M | -28.12M | -64.42M | -60.74M |
Balance Sheet | |||||
| Total Assets | 112.71M | 167.96M | 152.31M | 171.32M | 209.58M |
| Cash, Cash Equivalents and Short-Term Investments | 92.37M | 149.41M | 131.37M | 94.78M | 187.52M |
| Total Debt | 13.99M | 17.22M | 21.80M | 21.97M | 60.37M |
| Total Liabilities | 63.36M | 79.40M | 106.59M | 104.64M | 96.35M |
| Stockholders Equity | 49.35M | 88.56M | 45.72M | 67.06M | 113.83M |
Cash Flow | |||||
| Free Cash Flow | -51.69M | -37.81M | 20.18M | -69.22M | -26.50M |
| Operating Cash Flow | -50.71M | -36.39M | 21.55M | -68.51M | -26.01M |
| Investing Cash Flow | -979.74K | -4.07M | 4.28M | -702.00K | -425.00K |
| Financing Cash Flow | -1.76M | 70.28M | -2.27M | -30.89M | 136.83M |
ProQR Technical Analysis
Negative
1.50
Price Trends
1.60
Negative
1.88
Negative
2.06
Negative
Market Momentum
-0.02
Positive
41.81
Neutral
18.39
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRQR, the sentiment is Negative. The current price of 1.5 is below the 20-day moving average (MA) of 1.67, below the 50-day MA of 1.60, and below the 200-day MA of 2.06, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 41.81 is Neutral, neither overbought nor oversold. The STOCH value of 18.39 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PRQR.
ProQR Risk Analysis
ProQR disclosed 81 risk factors in its most recent earnings report. ProQR reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ProQR Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $424.65M | -1.84 | -46.34% | ― | ― | 14.33% | |
55 Neutral | $228.76M | -4.17 | -22.37% | ― | 3.36% | 5.15% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $150.84M | -3.23 | -90.51% | ― | -17.87% | 14.42% | |
46 Neutral | $158.04M | -5.01 | -99.45% | ― | -11.99% | -42.04% | |
45 Neutral | $155.56M | -18.34 | 304.91% | ― | 12.60% | 58.23% |
* Healthcare Sector Average
PRQR
ProQR
1.50
0.07
4.90%
CDXS
Codexis
1.66
-1.26
-43.15%
HRTX
Heron Therapeutics
0.83
-1.49
-64.29%
TLSA
Tiziana Life Sciences
1.25
0.11
9.65%
AVIR
Atea Pharmaceuticals
5.33
2.31
76.49%
OABI
OmniAb
1.58
-0.89
-36.03%
ProQR Corporate Events
ProQR Sets April 8 Virtual Investor Event to Spotlight Axiomer RNA Editing Pipeline
Mar 25, 2026
On March 25, 2026, ProQR Therapeutics announced it will host a virtual Investor and Analyst Event on April 8, 2026, to showcase its expanding pipeline of RNA editing therapies built on the Axiomer platform. The event, titled “Expanding the A...
ProQR Posts 2025 Results as Axiomer RNA Editing Pipeline Advances and Cash Runway Extends to Mid-2027
Mar 12, 2026
On March 12, 2026, ProQR reported its operating and financial results for the year ended Dec. 31, 2025, highlighting progress on lead candidate AX-0810 for cholestatic diseases, which is in an ongoing Phase 1 multiple-dose study in healthy volunte...
ProQR Therapeutics Plans Board Changes as Co-Founder and Director Exit at 2026 AGM
Feb 9, 2026
On February 9, 2026, ProQR Therapeutics announced planned changes to its board of directors, with co-founder Dinko Valerio and director Alison Lawton set to rotate off the board at the company’s 2026 Annual General Meeting as their terms con...
ProQR Reports Positive AX-0810 Phase 1 Data, Advances Rett and MASH Candidates, and Outlines 2026 Pipeline Plans
Jan 8, 2026
On January 8, 2026, ProQR reported encouraging initial Phase 1 data for its lead candidate AX-0810, showing no serious safety issues and pharmacokinetics in line with preclinical findings after four weeks of dosing in the first cohort of healthy v...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.